Catalent

52 articles about Catalent

• Catalent to Hold Business Update Call Related to Delay of Third Quarter 2023 Results and Receives NYSE Notice Regarding Late Form 10-Q Filing

  5/19/2023

  Catalent to Hold Business Update Call Related to Delay of Third Quarter 2023 Results and Receives NYSE Notice Regarding Late Form 10-Q Filing.

• Catalent Announces Postponement of Third Quarter 2023 Results and Conference Call

  5/13/2023

  Catalent, Inc. announced it will be postponing the release of its financial results for the third quarter of fiscal year 2023, ended March 31, 2023, and the conference call previously scheduled for Monday, May 15, 2023 at 8:15 a.m.

• 

  Catalent Delays Earnings Call, Shaves $400M Off FY23 Guidance

  5/9/2023

  The delay and guidance downgrade follow a spate of operational issues that have affected three of Catalent’s major manufacturing sites.

• Catalent Delays Third Quarter Results and Conference Call and Provides Update on Fiscal 2023 Guidance

  5/8/2023

  Catalent, Inc. today announced that it will be delaying the release of its third fiscal quarter results and investor conference call, previously scheduled for Tuesday, May 9, 2023.

• Catalent Recommends Stockholders Reject Mini-Tender Offer From TRC Capital Investment Corporation

  5/5/2023

  Catalent, Inc. (“Catalent”) (NYSE: CTLT) has been notified of an unsolicited “mini-tender offer” by TRC Capital Investment Corporation (“TRC”) to purchase up to 2,000,000 shares of Catalent’s common stock at a price of $42.95 per share in cash.

• Catalent Provides Business Update and Names Ricky Hopson as Interim Chief Financial Officer

  4/14/2023

  Catalent, Inc. today announced a business update.

• Catalent, Inc. to Present at March Investor Conferences

  3/9/2023

  Catalent, Inc. today announced that members of its executive leadership team will participate at two upcoming investor conferences.

• Catalent Publishes Fourth Annual Corporate Responsibility Report Highlighting Achievements While Providing New Record Number of Patient Treatments

  2/28/2023

  Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, published its fourth Corporate Responsibility Report for its fiscal year 2022, which ended June 30, 2022.

• Catalent, Inc. Reports Second Quarter Fiscal 2023 Results

  2/7/2023

  Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced financial results for the second quarter of fiscal 2023, which ended December 31, 2022.

• Catalent, Inc. Announces Second Quarter Fiscal Year 2023 Earnings Conference Webcast

  1/20/2023

  Catalent, Inc. today announced that it will release financial results for the second quarter of fiscal year 2023 ended December 31, 2022, before the market open on Tuesday, February 7, 2023.

• Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader

  1/17/2023

  Catalent, Inc. today announced the appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America.

• Avantor® and Catalent Enter into Multi-Year Supply and Services Agreement

  1/9/2023

  Avantor, Inc. today announced that it has entered into a multi-year supply and services agreement with Catalent, Inc.

• Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate

  1/5/2023

  Catalent, Inc. and Sarepta Therapeutics, Inc. today announced the signing of a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec (SRP-9001), Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy (DMD).

• Catalent Announces Changes to its Board of Directors - December 19, 2022

  12/19/2022

  Catalent, Inc. today announced that current board member and lead independent director J. Martin (“Marty”) Carroll has been unanimously selected by its Board of Directors to succeed John Chiminski and serve as Chair following Mr. Chiminski’s retirement.

• Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline

  11/3/2022

  Exelixis, Inc. (Nasdaq: EXEL) and Catalent, Inc. (NYSE: CTLT) today announced a new license agreement under which Catalent’s Redwood Bioscience subsidiary will grant Exelixis an exclusive license to three target programs with lead antibody and/or ADC candidates.

• Catalent, Inc. Reports First Quarter Fiscal 2023 Results

  11/1/2022

  Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced financial results for the first quarter of fiscal 2023, which ended September 30, 2022.

• Catalent, Inc. Announces First Quarter Fiscal Year 2023 Earnings Conference Webcast

  10/17/2022

  Catalent, Inc. announced that it will release financial results for the first quarter of fiscal year 2023 ended September 30, 2022, before the market open on Tuesday, November 1, 2022.

• Catalent, Inc. to Present at September 2022 Investor Conferences

  9/8/2022

  Catalent, Inc. announced that members of its executive leadership team will participate at two upcoming investor conferences.

• Catalent, Inc. Reports Fourth Quarter Fiscal 2022 Results

  8/29/2022

  Catalent, Inc. today announced financial results for the fourth quarter of fiscal 2022, which ended June 30, 2022.

• Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity

  8/9/2022

  Catalent, Inc. announced that it has reached an agreement to acquire Metrics Contract Services, a full-service specialty Contract Development and Manufacturing Organization with a facility in Greenville, North Carolina, for $475 million from Mayne Pharma Group Limited .